VJOncology Podcast

This week, VJOncology brings you lung cancer highlights from the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. Join Alessandro di Federico from the Memorial Sloan Kettering Cancer Center, Erika Ruiz-Garcia of the Instituto Nacional de Cancerologia, Nandini Menon of the Tate Memorial Centre and Bjorn Henning Gronberg of the Norwegian University of Science and Technology as they discuss key trials and data in lung cancer from the meeting. They explore results from the LIBRETTO-432, TRITON and FLAME trials, as well as 7-year follow up data from the CROWN trial. In addition, they discuss two trials of KRAS G12C inhibitors, a study examining low-dose pembrolizumab and a trial of thoracic radiotherapy.

This podcast examines immunotherapy’s expanding role across gastrointestinal cancers, from perioperative to adjuvant settings. Experts discuss perioperative immunotherapy strategies for gastric and gastroesophageal junction cancers, including findings from the NEOSUMMIT-01 trial. The KEYNOTE-937 trial is explored, addressing the challenging adjuvant setting in hepatocellular carcinoma after curative-intent treatment. The KEYSTEP-008 platform trial findings highlight optimizing pembrolizumab-based combinations in MSI-high, mismatch repair deficient metastatic colorectal cancer. Finally, emerging biomarkers beyond microsatellite instability are discussed, including the TAPUR trial evaluating dual checkpoint inhibition in colorectal cancer patients with BRCA1/2 alterations. These insights showcase immunotherapy’s transformative potential in GI malignancies.

In this week’s VJOncology podcast, the first of 2026, we bring you key updates in the use of artificial intelligence (AI) in oncology and how it will impact clinicians and patients alike. Join renowned experts Anita Grigoriadis, PhD, King’s College London, London, UK, Rosalind Picard, ScD, MIT Media Lab, Cambridge, MA, Jana Lipkova, PhD, University of California, Irvine, CA, and Roberto Salgado, MD, PhD, Peter MacCallum Cancer Centre, Melbourne, Australia as they comment on how to increase AI literacy for oncologists, identifying patients with high-risk lobular breast cancer with AI, and more.

In this week’s VJOncology podcast, we will be covering highlights from ESMO 2025 in Berlin, Germany. Gain expert insights in the field of genitourinary cancers, including highly-anticipated trial results, emerging biomarkers in kidney cancer, and the evolving role of radionuclides in prostate cancer. Join renowned speakers Andrea Necchi, MD, IRCCS San Raffaele Hospital and Scientific Institute, Milan, Italy, Sara Coca Membribes, MD, Barts Health NHS Trust, London, UK, Scott Tagawa, MD, MS, FACP, Weill Cornell Medical Center, New York, NY, Paul Nguyen, MD, MBA, Dana-Farber Cancer Institute, Boston, MA, as they discuss trials such as GDFather-NEO, CALYPSO, and more.

In this episode of the VJOncology Podcast, we bring you four standout interviews from ESMO 2025 that are reshaping the way we think about lung cancer. From antibody-drug conjugates and bispecific T-cell engagers through novel HER2-targeted TKIs to tumour-immune microenvironment biomarkers, the treatment paradigm is evolving rapidly. Join us as we explore findings from the Phase III OptiTROP-Lung04 study of sacituzumab tirumotecan in EGFR-mutant non-small-cell lung cancer (NSCLC) post-TKI progression, safety analysis of DeLLphi-304: tarlatamab vs standard chemo in small-cell lung cancer (SCLC), the first-line Beamion LUNG-1 experience of zongertinib in advanced HER2-mutant NSCLC and biomarker insights from the ImmunoDriver-2 analysis. We’ll weave together how these advances hint at a future where molecular and immunologic profiling come together: identifying patients who will benefit most, integrating new treatment classes, and navigating safety/survivorship in more complex regimens.

In this week’s VJOncology podcast, leading experts share the latest updates in ADCs in HER2-positive and metastatic breast cancer in recognition of Breast Cancer Awareness Month. Charles Geyer, MD, discusses pivotal results from the Phase III DESTINY-Breast05 trial, where trastuzumab deruxtecan (T-DXd) significantly improved invasive disease-free and disease-free survival versus trastuzumab emtansine (T-DM1) in high-risk HER2-positive early breast cancer, reducing the risk of brain metastases. Sara Tolaney, MD, MPH, highlights the practice-changing reduction in recurrence risk with T-DXd and comments on the expanding role of antibody–drug conjugates (ADCs) in earlier lines of therapy across breast cancer subtypes, referencing data from DESTINY-Breast09 and ASCENT-03. Finally, Erika Hamilton, MD, reviews the advancement of ADCs into the curative setting through DESTINY-Breast11 and discusses emerging combination strategies and first-line use in triple-negative breast cancer, emphasizing the growing importance of ADCs in modern breast cancer care.